International Journal of Infectious Diseases
Volume 14, Issue 2 , Pages e90-e95 , February 2010

Prevalence and antibiotic susceptibility of Mycoplasma hominis and Ureaplasma urealyticum in pregnant women

  • Mehmet Refik Bayraktar

      Affiliations

    • Department of Medical Microbiology, Faculty of Medicine, Inonu University, 44315 Malatya, Turkey
    • Corresponding Author InformationCorresponding author. Fax: +90 422 3410036.
    • ,
  • Ibrahim Halil Ozerol

      Affiliations

    • Department of Medical Microbiology, Faculty of Medicine, Inonu University, 44315 Malatya, Turkey
    • ,
  • Nilay Gucluer

      Affiliations

    • Department of Medical Microbiology, Faculty of Medicine, Inonu University, 44315 Malatya, Turkey
    • ,
  • Onder Celik

      Affiliations

    • Department of Gynecology and Obstetrics, Medical School, Inonu University, Malatya, Turkey

Received 24 October 2008 ,Revised 18 February 2009 ,Accepted 13 March 2009.

References 

  1. Cassell GH, Waites KB, Watson HL, Crouse DT, Harasawa R. Ureaplasma urealyticum intrauterine infection: role in prematurity and disease in newborns. Clin Microbiol Rev. 1993;6:69–87
  2. Taylor-Robinson D, Furr PM. Update on sexually transmitted mycoplasmas. Lancet. 1998;351(Suppl 3):12–15
  3. Daxboeck F, Zitta S, Stadler M, Iro E, Krause R. Mycoplasma hominis and Ureaplasma urealyticum in patients with sterile pyuria. J Infect. 2005;51:54–58
  4. Patai K, Szilágyi G, Hubay M, Szentmáriay IF, Paulin F. Severe endometritis caused by genital mycoplasmas after Caesarean section. J Med Microbiol. 2005;54:1249–1250
  5. Witt A, Berger A, Gruber CJ, Petricevic L, Apfalter P, Worda C, et al. Increased intrauterine frequency of Ureaplasma urealyticum in women with preterm labor and preterm premature rupture of the membranes and subsequent cesarean delivery. Am J Obstet Gynecol. 2005;193:1663–1669
  6. Pararas MV, Skevaki CL, Kafetzis DA. Preterm birth due to maternal infection: causative pathogens and modes of prevention. Eur J Clin Microbiol Infect Dis. 2006;25:562–569
  7. van Belkum A, van der Schee C, van der Meijden WI, Verbrugh HA, Sluiters HJ. A clinical study on the association of Trichomonas vaginalis and Mycoplasma hominis infections in women attending a sexually transmitted disease (STD) outpatient clinic. FEMS Immunol Med Microbiol. 2001;32:27–32
  8. Waites KB, Katz B, Schelonka RL. Mycoplasmas and ureaplasmas as neonatal pathogens. Clin Microbiol Rev. 2005;18:757–789
  9. Zdrodowska-Stefanow B, Kłosowska WM, Ostaszewska-Puchalska I, Bułhak-Kozioł V, Kotowicz B. Ureaplasma urealyticum and Mycoplasma hominis infection in women with urogenital diseases. Adv Med Sci. 2006;51:250–253
  10. Clegg A, Passey M, Yoannes M, Michael A. High rates of genital Mycoplasma infection in the highlands of Papua New Guinea determined both by culture and by a commercial detection kit. J Clin Microbiol. 1997;35:197–200
  11. Domingues D, Távora Tavira L, Duarte A, Sanca A, Prieto E, Exposto F. Genital mycoplasmas in women attending a family planning clinic in Guiné-Bissau and their susceptibility to antimicrobial agents. Acta Trop. 2003;86:19–24
  12. Keane FE, Thomas BJ, Gilroy CB, Renton A, Taylor-Robinson D. The association of Mycoplasma hominis, Ureaplasma urealyticum and Mycoplasma genitalium with bacterial vaginosis: observations on heterosexual women and their male partners. Int J STD AIDS. 2000;11:356–360
  13. Arya OP, Tong CY, Hart CA, Pratt BC, Hughes S, Roberts P, et al. Is Mycoplasma hominis a vaginal pathogen?. Sex Transm Infect. 2001;77:58–62
  14. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin–dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines and quinolones. Antimicrob Agents Chemother. 2001;45:2604–2608
  15. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74:14–22
  16. Egan ME, Lipsky MS. Diagnosis of vaginitis. Am Fam Physician. 2000;62:1095–1104
  17. Grattard F, Soleihac B, De Barbeyrac B, Bebear C, Seffert P, Pozzetto B. Epidemiologic and molecular investigations of genital mycoplasmas from women and neonates at delivery. Pediatr Infect Dis J. 1995;14:853–858
  18. Kechagia N, Bersimis S, Chatzipanagiotou S. Incidence and antimicrobial susceptibilities of genital mycoplasmas in outpatient women with clinical vaginitis in Athens, Greece. J Antimicrob Chemother. 2008;62:122–125
  19. Kataoka S, Yamada T, Chou K, Nishida R, Morikawa M, Minami M, et al. Association between preterm birth and vaginal colonization by mycoplasmas in early pregnancy. J Clin Microbiol. 2006;44:51–55
  20. McDonald HM, O’Loughlin JA, Jolley PT, Vigneswaran R, McDonald PJ. Changes in vaginal flora during pregnancy and association with preterm birth. J Infect Dis. 1994;170:724–728
  21. Kundsin RB, Leviton A, Allred EN, Poulin SA. Ureaplasma urealyticum infection of the placenta in pregnancies that ended prematurely. Obstet Gynecol. 1996;87:122–127
  22. McGregor JA, French JI. Bacterial vaginosis in pregnancy. Obstet Gynecol Surv. 2000;55(Suppl 1):S1–19
  23. Chaim W, Mazor M, Leiberman JR. The relationship between bacterial vaginosis and preterm birth. Arch Gynecol Obstet. 1997;259:51–58
  24. Taylor-Robinson D, Bebear C. Antibiotic susceptibilities of mycoplasmas and treatment of mycoplasmal infections. J Antimicrob Chemother. 1997;40:622–630
  25. Semra Z, Rosenberg S, Soffer Y. In vitro susceptibility of Mycoplasma hominis clinical isolates to tetracyclines, quinolones and macrolides. Diagn Microbiol Infect Dis. 2002;44:359–361
  26. Ullmann U, Schubert S, Krausse R. Comparative in vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis. J Antimicrob Chemother. 1999;43(Suppl C):33–36
  27. Bebear CM, Renaudin H, Charron A, Gruson D, Lefrancois M, Bebear C. In vitro activity of trovafloxacin compared to those of five antimicrobials against mycoplasmas including Mycoplasma hominis and Ureaplasma urealyticum fluoroquinolone-resistant isolates that have been genetically characterized. Antimicrob Agents Chemother. 2000;44:2557–2560

PII: S1201-9712(09)00156-8

doi: 10.1016/j.ijid.2009.03.020

International Journal of Infectious Diseases
Volume 14, Issue 2 , Pages e90-e95 , February 2010

Article Tools